Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Role of Cholesterol in the Etiology and Pathogenesis of Alzheimer's Disease

Role of Cholesterol in the Etiology and Pathogenesis of Alzheimer's Disease

Tuesday, May 23, 2006

The New York Academy of Sciences

Organizers: Lit-Fui Lau, Pfizer; and June Sonnenberg, Wyeth


Alzheimer's disease (AD) afflicts 4.5 million people in the United States. It poses a huge socioeconomic burden that could mushroom out of control in light of the aging population and the absence of effective treatments that slow disease progression. Although a number of familial AD genes have been identified, the majority of AD cases remain sporadic, suggesting a significant role of environmental factors in its etiology. Among these factors, cholesterol has received much attention. Association of cholesterol with AD has been revealed by epidemiology, human genetics, clinical studies, and in vitro and in vivo preclinical models. Importantly, efficacious and safe agents in regulating cholesterol metabolism are available and more are being developed. A clear understanding of the interaction between cholesterol metabolism and AD pathogenesis will help us understand broader opportunities in the treatment of this pernicious disease.

Program

 

1:00

Introduction

Lit-Fui Lau, Pfizer


1:10

Benjamin Wolozin, Boston University, Massachusetts, "Cholesterol, Statins and AD."

2:05

Gopal Thinakaran, The University of Chicago, Illinois, "Processing of APP in Cholesterol-Rich Membrane Microdomains."

3:00

Coffee Break

3:20

Karl Weisgraber, Gladstone Institute, University of California, San Francisco, "Role of ApoE4 Structure in AD."

4:15

Cheryl Wellington, University of British Columbia, Vancouver, "ABCA1, ApoE and Amyloid Deposition in AD."

5:10

Adjourn